

New Molecular Entities: A European Comparison

Market share of new molecular entities launched during the past five years in percent



As of: 2007

Source: Pharmaceutical associations of the European countries, vfa

When it comes to enthusiasm for innovation, Germany ranks near the bottom in Europe. In 2007, only 6.0 percent of expenditures in Germany were made for innovative pharmaceuticals launched during the previous five years. As a result, Germany spends less on novel pharmaceuticals than most other European countries, despite the fact that an equally large number of pharmaceuticals receive marketing authorization domestically. However, they are prescribed less frequently or they have lower prices.